Heather Landi

2 weeks ago | fiercehealthcare.com | Heather Landi

Google Cloud continues to quickly build out its generative AI capabilities and is advancing technology for the adoption and use of AI agents that can automate tasks and collaborate across organizations. At Google Cloud Next 2025 today, the company announced new tools and services in Vertex AI, such as an agent development kit and Agent2Agent protocol that enable a multi-agent ecosystem.

2 weeks ago | fiercehealthcare.com | Heather Landi

Walgreens reported a loss of $2.85 billion in its fiscal second quarter, pulled down by a hefty impairment charge related to its investment in primary care business VillageMD and its U.S. retail pharmacy business. The company reported a second quarter loss per share of $3.30 compared to loss per share of $6.85 the year-ago quarter. The company reported a loss of $5.9 billion in Q2 2024.

2 weeks ago | fiercehealthcare.com | Heather Landi

2025 kicked off with big digital health and healthcare AI fundraises, tech partnerships, M&A deals, including DispatchHealth and Medically Home's tie-up, and plans for a potential blockbuster IPO. Against this backdrop, the first three months of 2025 also saw a steady volume of funding deals, as digital health startups raised $3 billion, compared to $2.7 billion raised the same quarter last year. There were 122 funding deals in Q1 compared to 133 the same quarter a year ago.

2 weeks ago | fiercehealthcare.com | Heather Landi

A second school-age child in Texas has died from measles amid a fast-growing, multistate outbreak that now totals more than 600 cases nationally. Texas' Department of State Health Services reported Sunday that a school-aged child who tested positive for measles was hospitalized in Lubbock and passed away Thursday from what the child’s doctors described as measles pulmonary failure. The child was not vaccinated and had no reported underlying conditions, state officials reported.

3 weeks ago | fiercehealthcare.com | Heather Landi

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform. In a blog post on Tuesday, the online health and wellness company said it would offer generic liraglutide and branded tirzepatide, the key ingredient in Zepbound and Mounjaro, in addition to oral medication kits, compounded semaglutide and branded semaglutide.